Novel conjugates for targeted drug delivery

A method of preparation of a pharmaceutical formulation comprising a triple conjugate wherein said triple conjugate comprises a polymer moiety, a protein moiety, and an active drug moiety comprising one or more active drug(s), said method comprising the steps of:

• (i) preparing a complex of said polymer moiety and said protein moiety by addition of said polymer moiety to said protein moiety to obtain a polymer-protein complex following addition of said drug moiety;
• or
• (ii) adding said polymer moiety, said protein moiety and said drug moiety simultaneously to facilitate a conjugation;
• wherein said active drug moiety and said protein moiety are chemically different to each other;
• and
• wherein said active drug moiety is non-biological entity.

A method of treating or preventing a disease condition selected form the group comprising of neoplastic diseases, autoimmune diseases, GERD, Ulcer, Autoimmune conditions, Diabetes, Genetic conditions, Viral/Bacterial/Parasitic Infections, Worm conditions, Physical conditions, Prion diseases, Nutritional deficiencies, Vitamin/Mineral deficiencies Mitochondrial diseases, Accidents, Sexually Transmitted Diseases, Pregnancy Conditions, Breastfeeding Conditions, Birth defects, Male/Female/Infant/childhood/Adolescent conditions, Immune disorders, Balance disorders, Pain, Systemic disorders, Blood conditions, Blood vessel conditions, Nerve conditions, Muscle conditions, Heart conditions, Back/Neck/Spinalcord conditions, Eye conditions, Brain conditions, Mental conditions, Nose conditions, Mouth conditions, Dental conditions, Foot/Leg/Knee conditions, upper limb condition, Shoulder conditions, Ear conditions, Lung conditions, Liver conditions, Kidney conditions, Gall bladder conditions, Pancreas conditions, Digestive conditions, Prostate conditions, Male genital conditions, Obstetrical conditions, Gynaecological conditions, Thyroid disorders, or Hearing disorders, comprising administering a therapeutically effective amount of pharmaceutical formulation comprising triple conjugate wherein said triple conjugate comprises a polymer moiety, a protein moiety and an active drug moiety, to a subject in need thereof;

• wherein said active drug moiety and said protein moiety are chemically different to each other;
• and
• wherein said active drug moiety is non-biological entity.